

Special Issue: Cell Cycle

## Review

## Divide or Conquer: Cell Cycle Regulation of Invasive Behavior

Abraham Q. Kohrman<sup>1</sup> and David Q. Matus<sup>1,\*,@</sup>

Cell invasion through the basement membrane (BM) occurs during normal embryonic development and is a fundamental feature of cancer metastasis. The underlying cellular and genetic machinery required for invasion has been difficult to identify, due to a lack of adequate *in vivo* models to accurately examine invasion in single cells at subcellular resolution. Recent evidence has documented a functional link between cell cycle arrest and invasive activity. While cancer progression is traditionally thought of as a disease of uncontrolled cell proliferation, cancer cell dissemination, a critical aspect of metastasis, may require a switch from a proliferative to an invasive state. In this work, we review evidence that BM invasion requires cell cycle arrest and discuss the implications of this concept with regard to limiting the lethality associated with cancer metastasis.

## Linking Cell Invasion and Cell Cycle Regulation

The **basement membrane** (BM; see [Glossary](#)), or basal lamina, is a specialized form of **extracellular matrix** and a metazoan innovation [1,2] that likely helped support the evolution of the three-dimensional body plan [3,4]. Structurally composed of polymeric laminin and crosslinked type IV collagen networks, the BM is a thin, dense, sheetlike material that provides structural support for epithelial and endothelial tissues and functions as a barrier limiting cellular movement [5]. However, specific cell types, notably those involved in embryogenesis and cancer, have evolved the ability to actively breach or cross BM barriers by adopting an invasive phenotype [5,6] ([Figure 1](#)).

Cell **invasion** is a morphogenetic behavior that results in the penetration of tissue barriers including the BM and, in vertebrates, the interstitial type I collagen from the stroma [7,8]. Acquisition of invasive behavior requires both dynamic restructuring of the actin and microtubule cytoskeleton, along with changes in transcriptional and epigenetic states [9–11]. Cells can invade individually or collectively by maintaining cell–cell adhesions, led by highly protrusive ‘leader cells’ [12,13]. Invasive cells adopt either a mesenchymal or amoeboid morphology. Molecularly, mesenchymal and amoeboid invasion are defined differently, based on reliance of proteolytic versus Rho-associated protein kinase/actomyosin-dependent mechanisms, respectively [13–15]. While these different invasive behaviors are usually segregated in the cancer literature, it is becoming more apparent that many invasive cells, particularly during cancer progression, are plastic and can adopt different morphogenetic programs based on their local environment [13,14,16]. For those cells that utilize a mesenchymal invasion program, the switch from epithelial to mesenchymal cell morphology is often referred to as **epithelial to mesenchymal transition** (EMT), and occurs across a range of cell types throughout organismal development [17]. While defining EMT during cancer progression is more challenging [18],

## Trends

Cell-invasive behavior is critical during development and is dysregulated in disease states, including cancer metastasis.

The ability to adopt an invasive phenotype and breach a mechanical barrier such as the basement membrane may be regulated in a cell cycle-dependent fashion. This underlies a dichotomy between cell proliferation and cell invasion.


Invasion occurs primarily in a G<sub>1</sub>/G<sub>0</sub> cell cycle-arrested state, and expression of proinvasive genes driving epithelial to mesenchymal transition and F-actin cytoskeletal reorganization are associated with this cell cycle state.

Changes in the activity of cyclin-dependent kinase inhibitors and their target cyclins and cyclin-dependent kinases not only mediate the decision to enter or exit the cell cycle, but also may be critical to acquiring an invasive phenotype.

Therapeutics that cause G<sub>1</sub>/G<sub>0</sub> arrest, such as palbociclib, show great promise, but further research is required to ensure that these drugs do not inadvertently drive metastatic cancer progression.

<sup>1</sup>Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794-5215, USA  
@dave\_matus

\*Correspondence:  
david.matus@stonybrook.edu  
(D.Q. Matus).



Trends in Cell Biology

**Figure 1. Cell Invasion Occurs During Development and Cancer Metastasis.** (A–C) During development, cells acquire invasive phenotypes to facilitate mammalian embryo placentation (A), gastrulation in many organisms (B), and in neural crest delamination (C). (D) During cancer metastasis, cancer cells are invasive at multiple steps, including escape from the primary tumor, intravasation and extravasation from the bloodstream, and establishment of a secondary tumor at a distant site.

similar transitions between cell morphology have been documented [19]. For the purpose of this review, we refer to this morphogenetic switch in cancer as EMT.

At a cell biological level, invasion requires adhesion to and degradation of extracellular matrix components [8,20]. While, in many systems, **BM invasion** is often associated with **migration** through the stroma, it is important to note that cells require unique genetic control mechanisms to remove the BM, independent of the genetic networks that regulate cell migration [6,21]. The molecular and genetic mechanisms underpinning invasive cellular behavior have been challenging to elucidate. This is largely due to the difficulty of modeling this dynamic, complex behavior *in vitro* using artificial substrates. Fortunately, recent insights from traditional model systems including *Caenorhabditis elegans* [10,11,22], *Drosophila* [23], zebrafish [24], chick [25], and mouse [26–28] have begun to illuminate how cells breach BM *in vivo*.

**C. elegans anchor cell (AC) invasion** into the vulval epithelium during nematode larval development has proved particularly useful in decoupling invasion and migration to examine invasive cellular behavior [29] (Figure 2A). The AC, a specialized somatic gonadal cell, initiates uterine–vulval attachment by invading through the BMs separating these developing tissues [29]. As the nonmotile AC maintains adhesion to neighboring uterine cells, examination of this invasive event permits separation of invasion from migratory behavior. Furthermore, researchers can visualize *C. elegans* AC invasion through a fluorescently labeled BM using live-cell imaging [30].

Recent data from *C. elegans* AC invasion have linked cell cycle control with BM invasion [9], suggesting that invasive behavior may be functionally coupled to the proliferative states of various cell types. Specifically, the AC must be in the  $G_1/G_0$  phase of the cell cycle in order to invade [9]. However, it is unclear whether  **$G_1/G_0$  cell cycle arrest** represents a general principle of all invading cells. Here, we review the potential conservation of cell cycle arrest in the invasive

## Glossary

**Basement membrane:** a dense highly crosslinked sheet of polymeric laminin and type IV collagen forming the substrate for endothelia and epithelia and providing a barrier function for most cells.

**Basement membrane invasion:** the process by which cells remove basement membrane allowing contact between cell layers or passage through the basement membrane.

***Caenorhabditis elegans* anchor cell invasion:** an *in vivo* model system used to examine the process of basement membrane invasion, as a specialized somatic gonad cell, the anchor cell, breaches the underlying basement membrane to initiate uterine–vulval contact, allowing worms to passage eggs to the external environment.

**Cyclin-dependent kinase inhibitors:** a family of conserved eukaryotic proteins (p16<sup>INK4a</sup>, p21<sup>CIP1</sup>, p27<sup>KIP1</sup> in vertebrates) that inhibit the activity of G<sub>1</sub>/S phase cyclins (cyclins D and E) and cyclin-dependent kinases (CDK4/6 and CDK2).

**Delamination:** the process by which cells leave an epithelium to migrate elsewhere, or form a new epithelial layer. This process is often coupled with epithelial to mesenchymal transition.


**Epithelial to mesenchymal transition:** the morphogenetic process by which cells switch from an epithelial to mesenchymal morphology occurring during development and cancer metastasis.

**Extracellular matrix:** the scaffolding of proteins supporting and surrounding metazoan cells.

**$G_1/G_0$  cell cycle arrest:** a quiescent cellular state that occurs following mitosis, where a cell either temporarily pauses, prior to entering the S phase ( $G_1$ ) or permanently arrests ( $G_0$ ). As these cellular states can be difficult to distinguish, we will refer to this arrest point as  $G_1/G_0$  arrest for the purposes of this review.

**Invasion:** the morphogenetic process by which cells penetrate the basement membrane and, in vertebrates, remodel the extracellular matrix-derived stroma.

**Migration:** the process by which cells move from place to place.



Trends in Cell Biology

**Figure 2.** *Caenorhabditis elegans* Anchor Cell (AC) Invasion into the Vulval Epithelium Is a Tractable *In Vivo* Model to Examine Invasion at Single-Cell Resolution in Real Time.


For a Figure360 author presentation of Figure 2, see the figure online at <http://dx.doi.org/10.1016/j.tcb.2016.08.003#mmc1>.

(A) During the third larval stage of *C. elegans* development, the AC invades in a highly stereotyped fashion. Shortly after the AC is specified (top), the invasive AC localizes invadopodia along the basolateral surface in response to extracellular cues (netrin, red, from the ventral nerve cord, and an unknown cue from the vulval cells) from the microenvironment [11] (middle). Next, the AC breaches the basement membrane (BM), contacting the vulval precursor cells (VPCs) and initiating the uterine–vulval connection (bottom). Spinning-disc confocal images depict the AC (magenta, expressing *zmp-1* > mCherry) and BM, visualized by laminin::GFP (green), and 1° VPCs (green, expressing *egl-17* > GFP). (B) A single transcription factor, the nuclear hormone receptor, *nhr-67/tlx*, mediates AC invasion by maintaining the AC in a G<sub>1</sub>/G<sub>0</sub> cell cycle-arrested state (top, left). Loss of *nhr-67/tlx* results in mitotic ACs that fail to invade (bottom). (C) Induced expression of *cki-1* restores G<sub>1</sub>/G<sub>0</sub> arrest and rescues invasion (bottom) [9]. Scale bar, 5 μm. Images in (C) from [9].

cascade across Metazoa, in normal and pathological states. Whether metastatic invasive cells also require discrete cell cycle control is an open question with important implications for future therapeutics designed to regulate invasive behavior during pathogenic processes.

### Cell Cycle Regulation of Invasion During Development

Invasive behavior is a critical component of metazoan development. This section reviews literature that suggests that the acquisition of invasive behavior during development is specifically regulated in a cell cycle-dependent fashion. During mammalian embryo implantation



Trends in Cell Biology

**Figure 3. Cell Cycle State and Invasive Activity.** The activity of cyclin-dependent kinase inhibitors (CKIs: p21<sup>CIP1</sup>/p27<sup>KIP1</sup>/p16<sup>INK4a</sup>) inhibits G<sub>1</sub>/S phase cyclins and cyclin-dependent kinases (cyclin D/CDK4/6 and cyclin E/CDK2), inducing G<sub>1</sub>/G<sub>0</sub> cell cycle arrest and promoting quiescence and invasion. Reduced activity of CKIs results in increased levels of G<sub>1</sub>/S phase cyclins and CDKs, promoting cell cycle entry, preventing invasive behavior. New cancer therapeutics such as palbociclib limit tumor growth by inducing G<sub>1</sub>/G<sub>0</sub> cell cycle arrest by directly inhibiting CDK4/6 activity. CDK, cyclin-dependent kinase.

(Figure 1A), cytotrophoblasts, the first embryonic cell type to exhibit highly specialized functions, differentiate into extravillous trophoblasts, which then invade into the uterine lining, as the first step of placentation [31]. This differentiation event is regulated by several transcription factors [32] that control the expression of downstream effectors of trophoblast invasion, including adhesion molecules [33] and matrix metalloproteinases (MMPs) [34], and is required for the adoption of the invasive phenotype. To differentiate, extravillous trophoblasts exit the cell cycle in the G<sub>1</sub> phase and upregulate **cyclin-dependent kinase inhibitors** (CKIs) such as p16<sup>INK4a</sup>, p21<sup>CIP1</sup>, and p27<sup>KIP1</sup> [35]. Whether cell cycle arrest is required for these trophoblast cells to adopt an invasive phenotype is currently unknown.

EMT is often associated with invasiveness and appears to be regulated in a cell cycle-dependent fashion [36–40]. EMT-associated cell behaviors in development and cancer progression demonstrate a strong association between loss of proliferation through downregulation of mitotic cyclin/cyclin-dependent kinase (CDK) activity and upregulation of CKIs [36,40] (Figure 3 and Table 1, Key Table). In some animals, gastrulation proceeds through EMT-initiated cellular movements that include endomesodermal cells adopting an invasive phenotype and passing through a BM. In sea urchin (*Lytechinus variegatus*) gastrulation, primary mesenchyme cells cross the BM (Figure 1B) and divide only after invading into the blastocoel [41,42]. Similarly, during chick gastrulation, cells undergo an EMT associated with BM removal [25]. Whether invasive gastrulation movements such as these in urchins and chick require cell cycle arrest is currently unknown.

During vertebrate development, neural crest cells, a population of specialized migratory cells, give rise to melanocytes, craniofacial structures, including cartilage and bone, as well as smooth muscle, and peripheral and enteric neurons and glia. Neural crest cells undergo an EMT-like behavior as they delaminate, crossing the nascent BM that lies over the dorsal portion of the

## Key Table

Table 1. Evidence for Cell Cycle Regulation of Cancer Cell Invasion

Organ of origin	Cancer subtype	<i>In vivo</i> assays	<i>In vitro</i> assays	Findings	Refs
Melanoma		IHC of tumors for MITF and p27 <sup>KIP1</sup> , tumor formation assays using SK-MEL-28 cells.	Matrigel invasion assays performed on cell lines generated for this paper.	Cell cycle arrest is associated with metastatic potential.	[64]
		Histopathology of patient samples and mouse xenografts of melanoma cell lines for MITF and Ki-67.	Gene expression profiling and western blots performed on primary melanoma cells.	Invasive cells spend more time in G <sub>1</sub> and there is a switch between proliferation and invasion mediated by transcriptional changes.	[65]
		RNA-seq and IHC of individual human melanoma cells.	–	A subpopulation of malignant melanoma cells show a noncycling and chemoresistant signature based on transcriptome profile.	[66]
Epithelial	Multiple types	<i>In situ</i> hybridization for Snail in mouse embryos, along with staining for cell death and BrdU incorporation.	Caspase 3 activity assay and western blotting of MDCK and MCA3D cells.	Proliferation and metastatic behaviors are not necessarily linked.	[36]
	Basal cell carcinoma	IHC of patient tumor samples for Ki-67 and p16 <sup>INK4a</sup> .	–	Invasive cells are nonproliferative, express p16 <sup>INK4a</sup> , and likely are in G <sub>1</sub> /G <sub>0</sub> .	[67]
	Epidermoid carcinoma	–	Matrigel invasion, FACS, expression reporters, IF, ChIP of A431 cells.	After undergoing EMT, A431 cells repress the cell cycle by blocking cyclin D and become more invasive.	[68]
	Squamous cell carcinoma	Primary mouse keratinocytes, mouse xenograft, and inducible squamous cell carcinoma mice. Lineage tracing and metastases probed <i>in vivo</i> using immunofluorescence. FACS and RNA-seq performed on tumor cells.	Primary keratinocytes and tumor cells: IHC, immunofluorescence.	Tumor growth factor- $\beta$ (TGF- $\beta$ ) suppresses proliferation and promotes invasion in squamous cell carcinoma stem cells, through regulation of p21 <sup>CIP1</sup> , leading to chemotherapeutic resistance.	[87]

Table 1. (continued)

Organ of origin	Cancer subtype	<i>In vivo</i> assays	<i>In vitro</i> assays	Findings	Refs
Others	Gastric adenocarcinoma	–	Live-cell imaging of MKN45 cells expressing Fucci invading into a Gelfoam-based histoculture preparation.	Invading cancer cells are predominantly in G <sub>0</sub> /G <sub>1</sub> .	[57]
	Lung	Mouse xenografts of H460 cells, quantifying tumor growth and brachyury expression by IHC.	Matrigel invasion, IF, ChIP, FACS sorting, and western blots on A549 and H460 cells.	Brachyury blocks the cell cycle by activating p21 <sup>CIP1</sup> , rendering cancer cells less sensitive to chemotherapy.	[69]
	Hepatocellular carcinoma	–	AH130 cells: FACS sorting, cell cycle synchronization, and <i>in vitro</i> invasion assays.	Cells invade in the G <sub>1</sub> phase of the cell cycle.	[72]
Breast		Microarray analysis of cells collected by invasion into microneedles or chemotaxis, and intravital imaging of MTLn3 cells as rat xenograft or PyMT mouse tumor model.	–	Invasive cells upregulate genes associated with cell cycle arrest (i.e., p21 <sup>CIP1</sup> , p16 <sup>INK4a</sup> ), and downregulate those associated with proliferation.	[73–75]
		Quantification of spontaneous metastases in PyMT tumor and mouse xenograft models.	<i>In vitro</i> assays including Matrigel invasion and immunofluorescence (e.g., p21), using MCF-7, MCF10A, and MDA-MB-231 cells.	Loss of p21 <sup>CIP1</sup> or overexpression of cyclin E prevents metastasis by preventing state switching between invasion and proliferation.	[76]
		IHC of primary tumors for Ki-67 and cyclin D1 and cyclin E.	FACS sorting, Matrigel invasion, and live-cell imaging of MDA-MB-231/435/468 cells	Decreased cyclin D1/E makes cells more invasive, increased cyclin D1/E makes cells more proliferative. In patient tissue samples, more cyclin D1/E correlates with less invasion, and vice versa.	[77,78]
		Quantification of spontaneous and experimental metastases from MDA-MB-231 xenograft tumors in mice.	–	Cell proliferation and invasive behavior show an inverse correlative relationship, mediated by Arg/Abi2 and CSFR1 via TGF- $\beta$ signaling.	[79,80]

Table 1. (continued)

Organ of origin	Cancer subtype	<i>In vivo</i> assays	<i>In vitro</i> assays	Findings	Refs
Colon	Carcinoma	IHC of patient samples for Ki-67, p16 <sup>INK4a</sup> .	–	The invasive fronts of colon cancers are nonproliferative and express p16 <sup>INK4a</sup> . Cell cycle exit appears to be required for invasive behavior.	[81–84,86]
	Colorectal	IHC of patient samples	ChIP on DLD-1, HCT-116, LS174T, and SW480 cells.	The proportion of cells expressing p16 <sup>INK4a</sup> at the invasive front of the tumor inversely correlates with long-term patient survival.	[85]
Pancreatic		–	Matrigel invasion and gelatin degradation by secreted media performed on gamma-irradiated Panc-1, Suit-2, and Hs766T cells.	Gamma-irradiated cells with lower proliferative ability exhibit increased invasive potential.	[98]
		–	Microarray analysis, FACS, and IF on AsPC-1, Panc-1, and COLO 357 cells.	The CDK4/6 inhibitor palbociclib increases EMT and invasiveness.	[104]

BrdU, bromodeoxyuridine; ChIP, Chromatin Immunoprecipitation; EMT, epithelial to mesenchymal transition; FACS, fluorescence-activated cell sorting; FUCCI, fluorescence ubiquitin cell cycle indicator; IF, immunofluorescence; IHC, immunohistochemistry; PyMT, polyomavirus middle T.

neural tube [43] (Figure 1C). Trunk neural crest appears to delaminate at the G<sub>1</sub>/S phase transition [44], while the **delamination** of the cranial neural crest does not appear to be cell cycle dependent [45]. Live-cell imaging with fluorescence ubiquitin cell cycle indicator (FUCCI) has revealed that the majority of cranial neural crest cells following delamination are quiescent during their initial migration and show altered cell cycle dynamics dependent on their destination, with some cells rapidly proliferating and others exiting the cell cycle [46]. Unfortunately, the BM has never been visualized during live neural crest migration, making it difficult to draw conclusions related to cell cycle state as individual neural crest cells cross BM barriers.

### Development and Cancer: Two Sides of the Same Coin

Cancer cells hijack developmental regulatory programs and signaling pathways to execute the suite of behaviors required for metastasis. Thus, the same morphogenetic cell biological behaviors and molecular cues that are required for developmental processes such as gastrulation and neural crest delamination during embryogenesis are also utilized by tumor cells to proliferate, communicate with the surrounding microenvironment, and adopt an invasive phenotype [47]. For processes like cell invasion, which are challenging to study in the complex *in vivo* environments where they occur, insights gained from the study of simple developmental systems such as *C. elegans* AC invasion have been helpful in elucidating general principles underlying invasive behavior.

The single AC normally exists in a postmitotic, cell cycle-arrested state [9], where, in response to extracellular cues, F-actin and actin regulators are recruited to the basolateral surface of the AC, generating dynamic, F-actin-rich, protrusive, membrane-associated, punctate structures called invadopodia (Figure 2A) [11]. Through coordination by netrin signaling, a single invadopodium breaches the underlying BM, connecting the uterine and vulval tissues [11,29,30,48]. Intrinsically, AC invasion is under the control of the conserved AP-1 transcription factor, *fos-1a*, which regulates the activity of the MMP, *zmp-1* [22]. Loss of *fos-1a* results in the failure of the AC to breach the BM.

What evidence exists that cancer cells and the *C. elegans* AC share conserved genetic programs mediating invasive behavior? First, human orthologs of proinvasive genes that function during AC invasion (i.e., AP-1/Fos, EVI1, Netrin1, and integrins) have been shown to regulate invasion in mammalian cells [49–52]. Second, RNAi screens in *C. elegans* have identified novel proinvasive genes (i.e., NLK and the CCT complex), which when depleted in both breast and colon cancer cell lines resulted in inhibition of invasion [10]. Third, the AC utilizes invadopodia to breach the underlying BM [11,53,54] (Figure 2A). Based on data from cancer cell lines and a wealth of *in vitro* experimental data, invadopodia have been implicated in invasive behavior, but their significance *in vivo* has been controversial due to the difficulties associated with resolving subcellular structures with adequate temporal resolution in complex environments where invasion occurs in vertebrates. However, recent data from *C. elegans* demonstrate a functional requirement for G<sub>1</sub>/G<sub>0</sub> cell cycle arrest in the acquisition of an invasive phenotype *in vivo* [9].

A targeted RNAi screen identified the conserved NR2E1 class nuclear hormone receptor transcription factor, *nhr-67/tlx*, as a novel regulator of AC invasion. Loss of *nhr-67/tlx* results in the normally postmitotic AC entering the cell cycle, proliferating, and failing to invade (Figure 2B). Live-cell imaging revealed that mitotic ACs do not localize invadopodia, nor do they express proinvasive genes, including MMPs and F-actin regulators, suggesting that the entire invasion program is altered in cycling ACs. In support of the G<sub>1</sub>/G<sub>0</sub> phase of the cell cycle being critical for invasive activity, AC-specific expression of the CKI, *cki-1* (p21<sup>CIP1</sup>/p27<sup>KIP1</sup> homolog), induces G<sub>1</sub>/G<sub>0</sub> arrest in *nhr-67*-deficient ACs, and restores invadopodia formation and MMP expression, thereby rescuing invasion (Figure 2C) [9].



If the dichotomy between invasion and proliferation were solely based on the incompatibility of cell-invasive behavior and active cell division, then one could imagine that a pause in any phase of the cell cycle prior to mitosis could be permissive to invasive activity. Induced cell cycle arrest, however, in the S or G<sub>2</sub> phase fails to rescue the invasive activity of mitotic *nhr-67*-deficient ACs, implicating the G<sub>1</sub>/G<sub>0</sub> phase of the cell cycle as critical for the acquisition of an invasive phenotype [9]. Taken together, data from mammalian embryo placentation and EMT-like behaviors during gastrulation and neural crest delamination indicate that cell cycle arrest may be important for acquisition of an invasive phenotype. These data are strongly supported by genetic and live-cell imaging data from *C. elegans* AC invasion that clearly define a relationship between G<sub>1</sub>/G<sub>0</sub> cell cycle arrest and invasion [9]. The following section will highlight the cancer biology literature that also suggests that cell cycle regulation may be required during metastatic progression.

#### Cell Cycle Regulation of BM Invasion During Cancer Metastasis

Metastatic processes, particularly cell invasion, remain poorly understood *in vivo* [55], due to the difficulty of studying complex biological processes occurring deep within organisms. BM invasion is required at multiple steps in the course of metastasis: at the primary tumor, during intravasation and extravasation of blood vessels, and at new tissue compartments, where they can form secondary tumors [5,6,8,20] (Figure 1D). *In vitro* models of invasion using native BM, such as rat peritoneal BM [56], have not yet been used to assess the cell cycle state of invasive cells. Other biological membranes, such as gelatin [57], exist but the most prevalent model used for invasion assays is Matrigel, an extracellular matrixlike secretion of Engelbreth–Holm–Swarm sarcoma cells [58]. While Matrigel contains many of the same proteins as BM (e.g., laminin, type IV collagen, and nidogen), cellular invasion through Matrigel does not necessarily correlate with invasiveness *in vivo* [59]. Specifically, Matrigel has been shown to be more permissive to invasion and lacks the intricate network of covalently crosslinked type IV collagen found in endogenous BM [5,8,59,60]. Thus, the relationship between BM invasion and cell cycle state during cancer metastasis is poorly understood.

As cancer is primarily characterized by uncontrolled cell proliferation [61], it may initially seem counterintuitive that there exists a switch between cell proliferation and BM invasion. Nonetheless, there is mounting evidence that such a switch exists. Recent theoretical work using *in silico* metabolic modeling predicts that cancer cells that are able to switch to a less proliferative state when presented with physical barriers and fewer metabolic resources are more likely to not only survive but also to spread more efficiently to distant sites as compared to more proliferative tumor cells [62]. Importantly, this *in silico* model of invasive versus proliferative cancer cell behavior is based on experimental data, and provides a framework for others to test the interplay between proliferation and invasion that likely occurs in many cancers. Here, we review the potential link between cell cycle arrest and invasive behavior. Because of the evolving nature of the field, we have based our assessment of the cell cycle state of cancer cells during invasion on multiple experimental methodologies (Table 1). The strongest evidence stems from *in vivo* histopathological data. We have also included studies that utilize matrix invasion assays coupled with careful analysis of cell cycle state. As simultaneous studies of cell cycle and BM invasion remain challenging in living specimens, we have discussed work using measures of metastatic potential as a proxy for invasiveness. Much of the available data at present remain descriptive and correlative, and thus, our ability to make definitive statements about the cell cycle state of tumor cells actively invading BM is limited by the available cancer literature.

Evidence of a switch between proliferation and invasion stems from studies performed in a wide variety of cancer types (Table 1). For cancers of epithelial origin, the ability of cancer cells to undergo EMT has long been associated with invasiveness and other metastatic characteristics (reviewed in [19]). In epithelial cell lines, as in developmental systems, the developmental basic

helix–loop–helix (bHLH) transcription factors Snail and Slug have been shown to induce an EMT-like state [63]. Upon Snail-mediated induction of EMT in mammalian embryogenesis and cancer, cell cycle progression is impaired and the cell cycle is arrested in G<sub>1</sub>/G<sub>0</sub> through increased expression of p21<sup>CIP1</sup> [36]. In melanoma, the bHLH transcription factor MITF controls the switch between proliferative and invasive states [64]. Tumor samples with high MITF expression revealed enhanced invasiveness but decreased tumor size and growth rate [65,66]. In basal cell carcinomas, immunohistochemistry of tumors has shown that the invasive cell population is nonproliferative and expresses markers associated with G<sub>1</sub>/G<sub>0</sub> cell cycle arrest [67]. In addition, epidermoid carcinoma cell lines undergo EMT and reduce cyclin D1 levels, thereby enhancing invasiveness *in vitro* [68].

Cell cycle arrest may also be required for invasive behavior in lung cancer where prometastatic cell cycle arrest is mediated by the expression of p21<sup>CIP1</sup> and modulated by the T-box transcription factor, Brachyury [69], which also drives EMT in many contexts during embryonic development [70]. Reuse of developmental transcription factors in cancer is common [61]: in osteosarcomas, the transcription factor RUNX1 drives the expression of MMP9, a prometastatic gene, and is specifically expressed in the G<sub>1</sub> phase of the cell cycle [71]. Additionally, hepatocellular carcinoma cells invade during the G<sub>1</sub> phase of the cell cycle [72]. Thus, it appears that EMT-like behavior from multiple cancer types may be linked to G<sub>1</sub>/G<sub>0</sub> cell cycle arrest.

Perhaps, the strongest association between invasive cells and the G<sub>1</sub>/G<sub>0</sub> cell cycle state is seen in breast cancer metastasis [73–80]. Recent, correlative evidence from polyomavirus middle T oncogene (MMTV-PyMT) organoid culture showed that proliferation is not required for the acquisition of an invasive leader cell phenotype, delineated by the presence of cytokeratin (K14)+ cells, which are found at the invasive front in all major subtypes of human breast cancer [12]. Additionally, microarray analysis of invasive mouse xenograft tumor cells isolated by invasion into microneedles uncovered gene expression associated with the G<sub>1</sub>/G<sub>0</sub> phase of the cell cycle (i.e., p21<sup>CIP1</sup>), as well as an upregulation of genes associated with cell-invasive behavior (i.e.,  $\beta$ -catenin, and F-actin regulators such as *cdc42*) [73–75]. There also exists strong *in vivo* evidence for a proliferative to invasive switch, where direct perturbations of the cell cycle in mouse models of breast cancer revealed that the loss of p21<sup>CIP1</sup> decreases the ability of breast cancer cells to metastasize [76]. Specifically, p21<sup>CIP1</sup> null pyMT mammary tumors were hyperproliferative but less invasive both *in vitro* and *in vivo* [76]. As p21<sup>CIP1</sup> functions to regulate the activity of cyclin E (Figure 3), human breast cancer cell lines expressing a constitutively active cyclin E construct were also hyperproliferative and tenfold less invasive than control tumors in a mouse xenograft model [76].

Clinically, this also appears to be the case, as primary tumors show an inverse relationship between levels of G<sub>1</sub> and S phase cyclins (cyclin D1 and cyclin E, Figure 3) and the infiltration or invasiveness of the tumor [76–78]. Together, these data suggest that manipulation of CKIs and/or their target cyclins could limit invasive activity during breast cancer progression. Changes in the CKI/cyclin/CDK axis may not be unique to breast cancer, as histopathological studies have revealed that the invasive fronts of colonic adenocarcinomas do not express the proliferative marker Ki-67 [81–84] but do express p16<sup>INK4a</sup> [85,86] (Figure 3), indicating that invasive cells are disproportionately arrested in G<sub>1</sub>/G<sub>0</sub>. Additionally, it was recently shown in a squamous cell carcinoma mouse model that tumor growth factor- $\beta$  signaling positively regulates transcription of p21<sup>CIP1</sup>, leading to slower cycling of the invasive stem cells and increased resistance to chemotherapy [87]. Traditionally, CKIs (p21<sup>CIP1</sup>/p27<sup>KIP1</sup>/p16<sup>INK4a</sup>) are classified as tumor suppressors, as they limit cellular growth [88–90]. However, since manipulating the CKI/cyclin/CDK axis, which is required for cell cycle entry and exit, has profound effects on the invasive capacity of tumor cells, this raises the possibility that at least some ‘tumor suppressors’ might function as activators of metastasis (Figure 3).

### The Alternative Hypothesis: Invasion and Proliferation Are Not Exclusive Behaviors

Contrary to the hypothesis posed earlier, the majority of cancer studies assume a positive correlation between cell proliferation and cell-invasive activity. However, in most cases where this relationship is examined, the positive correlation obtained is based on *in vitro* assays, which do not simultaneously assess BM integrity and cell cycle state. In the case of *in vivo*, or histopathological work, often, population-level effects rather than single-cell-state changes are assessed. Indeed, two studies in oral squamous cell carcinoma indicated that proliferation is linked with increased invasion, based on the Ki-67 index at the invasive fronts of patient biopsies [91,92]. Similarly, a recent *in vivo* study using intravital imaging of an HCT-116 colorectal cancer cell line, with a FUCCI cell cycle biosensor, showed that the majority of cells infiltrating the stroma were primarily in the S/G<sub>2</sub>/M phases of the cell cycle [93]. This is in direct contrast to a study using invasive gastric adenocarcinoma cells in a Gelfoam-based invasion assay, where cells were observed to be predominantly in the G<sub>1</sub>/G<sub>0</sub> phase of the cell cycle [57].

One plausible explanation for how enhanced proliferation and invasion may be linked, as proposed in the aforementioned studies, is that highly proliferative tumors could initiate invasive behavior non-cell autonomously by recruiting stromal cells to facilitate dissemination and intravasation. Indeed, cancer-associated fibroblasts (CAFs) and tumor-associated macrophages are well known to mediate metastasis [94–96]. In this scenario, the cell cycle state of metastatic tumor cells would be irrelevant if tumor-associated immune cells were to mediate BM invasion of the cancer cells as well as subsequent stromal infiltration. This could also serve as an alternative explanation for the results shown in squamous cell carcinoma [91,92] and colorectal cancer cell lines [93], where CAFs have been shown to be critical in facilitating metastasis [96,97]. For example, *in vitro* live-cell imaging through matrix has shown that squamous cell carcinoma (SCC) cells can either follow directly behind CAFs or utilize tracks made by CAFs during their collective invasion, but are unable to invade without CAF assistance [96]. Although increased proliferation is a characteristic of CAFs, the cell cycle state of individual CAFs or macrophages during tumor dissemination and intravasation is currently unknown. Since cancer does not represent a single disease, but rather a myriad of many different disorders [61], it is possible that some cancers develop the ability to invade BM and proliferate simultaneously, either through the co-option of the host cells' invasive abilities, or through the acquisition of invasion on their own as the result of currently unknown genetic and/or epigenetic mechanisms. Regardless, these conflicts in the literature highlight the importance that should be placed on the development of new models to directly assess BM invasion and cell cycle state in both cancer cells and the surrounding microenvironment at the onset of metastatic behavior.

### Therapeutic Implications of Cell Cycle Regulation of Invasive Behavior

Traditional antineoplastic chemotherapeutics kill rapidly dividing cells. However, since invasive cells appear to exist in quiescent G<sub>1</sub>/G<sub>0</sub> arrest (Table 1), these invasive, metastatic cell populations remain when the bulk of the tumor is killed by classical antineoplastics. For example, sublethal irradiation, which blocks the G<sub>1</sub>/S phase checkpoint, increases the metastatic potential of gliomas [98]. Further research is necessary to determine if cell cycle arrest triggered by sublethal doses of DNA-damaging antineoplastic treatments can drive metastatic behaviors as well.

In 2015, the first antineoplastic chemotherapeutic drug to directly target the cell cycle, palbociclib (PD-0332991), was approved by the Food and Drug Administration for use in breast cancer treatment [99] and is currently being used in clinical trials to target other cancers [100]. Palbociclib and other drugs are inhibitors of CDK4/6, the G<sub>1</sub>/S phase transition checkpoint [101] (Figure 3). Experimental inhibition of the G<sub>1</sub>/S phase transition through genetic mechanisms such as overexpression of p21<sup>CIP1</sup> [102,103] or high levels of p16<sup>INK4a</sup> [85] have led to increased metastatic characteristics. As palbociclib similarly blocks cell cycle progression at the G<sub>1</sub>/S

phase transition, this raises the possibility that it may also drive invasive behavior. Notably, in pancreatic cancer cell lines, palbociclib is sufficient to induce EMT and drive an increase in Matrigel invasion [104]. Therefore, while antineoplastic chemotherapeutic drugs targeting the G<sub>1</sub> phase of the cell cycle show great promise, more work must be done to ensure that treatment regimens do not inadvertently drive metastatic progression by facilitating invasive cell behavior by inducing G<sub>1</sub>/G<sub>0</sub> cell cycle arrest.

### Concluding Remarks

We have reviewed literature demonstrating that a broad array of cancers switch between invasive and proliferative states, with evidence ranging from correlative Matrigel invasion assays to histopathological studies of primary tumor samples (Table 1). Together, these data argue that cell cycle arrest may be a requirement for the acquisition of invasive activity. Given recent functional data from a developmental invasion event in *C. elegans*, we suggest that G<sub>1</sub>/G<sub>0</sub> phase cell cycle arrest may be required broadly to properly execute invasive behavior.

In spite of this mounting evidence, our mechanistic understanding of the relationship between cell cycle control and cell invasion remains limited due to a lack of tools to accurately visualize BM *in vitro* or *in vivo* while assaying cell cycle state (see Outstanding Questions). Future use of microfluidics to analyze cells at single-cell resolution *in vitro* [105] paired with advanced imaging modalities, including light sheet microscopy [106] and dynamic cell cycle biosensors [107, 108], will hopefully provide a more accurate assessment of cell cycle state during invasion. These same advanced imaging techniques, particularly light sheet [109] and two-photon microscopy [110], allow for long-term vital imaging [27, 111–113] at cellular and subcellular resolution *in vivo*. Going forward, better *in vivo* models are needed. Genome editing combined with improved microscopy should allow simultaneous visualization of labeled BM and invasive cells at single-cell resolution. Pairing these new technologies with cell cycle perturbations across multiple cancer cell types will reveal if the many disparate observations illustrated here represent a deeply conserved evolutionary principle underlying cell-invasive behavior between organisms that last shared a common ancestor over 500 million years ago.

### Acknowledgments

The authors would like to thank Mathieu Boissan, R. Antonio Herrera, and Taylor Medwig for their feedback, as well as the two anonymous reviewers, whose comments greatly improved the manuscript. We also thank Taylor Medwig for confocal micrographs used in Figure 1. D.Q.M. is supported by the Carol M. Baldwin Foundation for Breast Cancer Research and by the National Institutes of Health, National Cancer Institute (R00-CA154870).

### References

- Matus, D.Q. *et al.* (2014) Cell division and targeted cell cycle arrest opens and stabilizes basement membrane gaps. *Nat. Commun.* 5, 13
- Ozbek, S. *et al.* (2010) The evolution of extracellular matrix. *Mol. Biol. Cell* 21, 4300–4305
- Hynes, R.O. and Naba, A. (2012) Overview of the matrisome – an inventory of extracellular matrix constituents and functions. *Cold Spring Harb. Perspect. Biol.* 4, a004903
- Doljanski, F. (2004) The sculpturing role of fibroblast-like cells in morphogenesis. *Perspect. Biol. Med.* 47, 339–356
- Rowe, R.G. and Weiss, S.J. (2008) Breaching the basement membrane: who, when and how? *Trends Cell Biol.* 18, 560–574
- Kelley, L.C. *et al.* (2014) Traversing the basement membrane *in vivo*: a diversity of strategies. *J. Cell Biol.* 204, 291–302
- Friedl, P. and Wolf, K. (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. *Nat. Rev. Cancer* 3, 362–374
- Glentis, A. *et al.* (2014) Assembly, heterogeneity, and breaching of the basement membranes. *Cell Adh. Migr.* 8, 236–245
- Matus, D.Q. *et al.* (2015) Invasive cell fate requires G<sub>1</sub> cell-cycle arrest and histone deacetylase-mediated changes in gene expression. *Dev. Cell* 35, 162–174
- Matus, D.Q. *et al.* (2010) *In vivo* identification of regulators of cell invasion across basement membranes. *Sci. Signal.* 3, ra35
- Hagedorn, E.J. *et al.* (2013) The netrin receptor DCC focuses invadopodia-driven basement membrane transmigration *in vivo*. *J. Cell Biol.* 201, 903–913
- Cheung, K.J. *et al.* (2013) Collective invasion in breast cancer requires a conserved basal epithelial program. *Cell* 155, 1639–1651
- Friedl, P. and Alexander, S. (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. *Cell* 147, 992–1009
- Wolf, K. *et al.* (2013) Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. *J. Cell Biol.* 201, 1069–1084
- Sabeh, F. *et al.* (2009) Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. *J. Cell Biol.* 185, 11–19
- Haeger, A. *et al.* (2015) Collective cell migration: guidance principles and hierarchies. *Trends Cell Biol.* 25, 556–566
- Revenu, C. and Gilmour, D. (2009) EMT 2.0: shaping epithelia through collective migration. *Curr. Opin. Genet. Dev.* 19, 338–342

### Outstanding Questions

Can individual cells switch between invasive and proliferative states and if so, what are the autonomous and environmental signals that dictate the ability to transition between these states?

Why is the G<sub>1</sub>/G<sub>0</sub> state associated with cell-invasive behavior? This review highlights the many cases in different cancers that show correlation between quiescence in G<sub>1</sub>/G<sub>0</sub> and increased invasiveness.

How can we ensure that cancer therapeutics that promote G<sub>1</sub>/G<sub>0</sub> cell cycle arrest do not inadvertently select for invasive cellular behavior?

Can we create better *in vivo* models that will allow for single-cell visual analyses paired with cell cycle perturbations and live imaging of basement membrane invasion? This will allow for further exploration of this dichotomy between proliferative and invasive cellular states.

18. Klymkowsky, M.W. and Savagner, P. (2009) Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. *Am. J. Pathol.* 174, 1588–1593
19. Ye, X. and Weinberg, R.A. (2015) Epithelial-mesenchymal plasticity: a central regulator of cancer progression. *Trends Cell Biol.* 25, 675–686
20. Sahai, E. (2005) Mechanisms of cancer cell invasion. *Curr. Opin. Genet. Dev.* 15, 87–96
21. Schaeffer, D. *et al.* (2014) Cellular migration and invasion uncoupled: increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition. *Mol. Cell Biol.* 34, 3486–3499
22. Sherwood, D.R. *et al.* (2005) FOS-1 promotes basement-membrane removal during anchor-cell invasion in. *Cell* 121, 951–962
23. Srivastava, A. *et al.* (2007) Basement membrane remodeling is essential for *Drosophila* disc eversion and tumor invasion. *Proc. Natl. Acad. Sci. U.S.A.* 104, 2721–2726
24. Seiler, C. *et al.* (2012) Smooth muscle tension induces invasive remodeling of the zebrafish intestine. *PLoS Biol.* 10, e1001386
25. Nakaya, Y. *et al.* (2008) RhoA and microtubule dynamics control cell-basement membrane interaction in EMT during gastrulation. *Nat. Cell Biol.* 10, 765–775
26. Hiramatsu, R. *et al.* (2013) External mechanical cues trigger the establishment of the anterior-posterior axis in early mouse embryos. *Dev. Cell* 27, 131–144
27. Kedrin, D. *et al.* (2008) Intravital imaging of metastatic behavior through a mammary imaging window. *Nat. Methods* 5, 1019–1021
28. Philippar, U. *et al.* (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. *Dev. Cell* 15, 813–828
29. Sherwood, D.R. and Sternberg, P.W. (2003) Anchor cell invasion into the vulval epithelium in *C. elegans*. *Dev. Cell* 5, 21–31
30. Ziel, J.W. *et al.* (2009) UNC-6 (netrin) orients the invasive membrane of the anchor cell in *C. elegans*. *Nat. Cell Biol.* 11, 183–189
31. Red-Horse, K. *et al.* (2004) Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. *J. Clin. Invest.* 114, 744–754
32. Janatpour, M.J. *et al.* (2000) Id-2 regulates critical aspects of human cytotrophoblast differentiation, invasion and migration. *Development* 127, 549–558
33. Damsky, C.H. *et al.* (1994) Integrin switching regulates normal trophoblast invasion. *Development* 120, 3657–3666
34. Librach, C.L. *et al.* (1991) 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. *J. Cell Biol.* 113, 437–449
35. Genbaeov, O. *et al.* (2000) A repertoire of cell cycle regulators whose expression is coordinated with human cytotrophoblast differentiation. *Am. J. Pathol.* 157, 1337–1351
36. Vega, S. *et al.* (2004) Snail blocks the cell cycle and confers resistance to cell death. *Genes Dev.* 18, 1131–1143
37. Tran, D.D. *et al.* (2011) Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. *Mol. Cancer Res.* 9, 1644–1657
38. Kalluri, R. and Weinberg, R.A. (2009) The basics of epithelial-mesenchymal transition. *J. Clin. Invest.* 119, 1420–1428
39. Grassi, M.L. *et al.* (2016) Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. *J. Proteomics* <http://dx.doi.org/10.1016/j.jprot.2016.06.009>
40. Iordanskaia, T. and Nawshad, A. (2011) Mechanisms of transforming growth factor  $\beta$  induced cell cycle arrest in palate development. *J. Cell. Physiol.* 226, 1415–1424
41. Saunders, L.R. and McClay, D.R. (2014) Sub-circuits of a gene regulatory network control a developmental epithelial-mesenchymal transition. *Development* 141, 1503–1513
42. Lyons, D.C. *et al.* (2012) Morphogenesis in sea urchin embryos: linking cellular events to gene regulatory network states. *Wiley Interdiscip. Rev. Dev. Biol.* 1, 231–252
43. Clay, M.R. and Halloran, M.C. (2013) Rho activation is apically restricted by Arhgap1 in neural crest cells and drives epithelial-to-mesenchymal transition. *Development* 140, 3198–3209
44. Burstyn-Cohen, T. and Kalcheim, C. (2002) Association between the cell cycle and neural crest delamination through specific regulation of G<sub>1</sub>/S transition. *Dev. Cell* 3, 383–395
45. Théveneau, E. *et al.* (2007) Ets-1 confers cranial features on neural crest delamination. *PLoS One* 2, e1142
46. Ridenour, D.A. *et al.* (2014) The neural crest cell cycle is related to phases of migration in the head. *Development* 141, 1095–1103
47. Aiello, N.M. and Stanger, B.Z. (2016) Echoes of the embryo: using the developmental biology toolkit to study cancer. *Dis. Model. Mech.* 9, 105–114
48. Wang, Z. *et al.* (2014) UNC-6 (netrin) stabilizes oscillatory clustering of the UNC-40 (DCC) receptor to orient polarity. *J. Cell Biol.* 206, 619–633
49. Johnston, I.M. *et al.* (2000) Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion. *Oncogene* 19, 5348–5358
50. Chen, H. *et al.* (2010) Netrin-1 signaling mediates NO-induced glial precursor migration and accumulation. *Cell Res.* 20, 238–241
51. Dumartin, L. *et al.* (2010) Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. *Gastroenterology* 138, 1595–1606. e1–1606.e8
52. White, D.E. and Muller, W.J. (2007) Multifaceted roles of integrins in breast cancer metastasis. *J. Mammary Gland Biol. Neoplasia* 12, 135–142
53. Hagedorn, E.J. *et al.* (2014) ADF/cofilin promotes invadopodial membrane recycling during cell invasion *in vivo*. *J. Cell Biol.* 204, 1209–1218
54. Lohmer, L.L. *et al.* (2016) A sensitized screen for genes promoting invadopodia function *in vivo*: CDC-42 and Rab GDI-1 direct distinct aspects of invadopodia formation. *PLoS Genet.* 12, e1005786
55. Valastyan, S. and Weinberg, R.A. (2011) Tumor metastasis: molecular insights and evolving paradigms. *Cell* 147, 275–292
56. Schoumacher, M. *et al.* (2010) Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. *J. Cell Biol.* 189, 541–556
57. Yano, S. *et al.* (2014) Invading cancer cells are predominantly in G<sub>2</sub>/G<sub>1</sub> resulting in chemoresistance demonstrated by real-time FUCCI imaging. *Cell Cycle* 13, 953–960
58. Benton, G. *et al.* (2011) Multiple uses of basement membrane-like matrix (BME/Matrigel) *in vitro* and *in vivo* with cancer cells. *Int. J. Cancer* 128, 1751–1757
59. Noël, A.C. *et al.* (1991) Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. *Cancer Res.* 51, 405–414
60. Vukicevic, S. *et al.* (1992) Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. *Exp. Cell Res.* 202, 1–8
61. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell* 144, 646–674
62. Hecht, I. *et al.* (2015) The motility-proliferation-metabolism interplay during metastatic invasion. *Sci. Rep.* 5, 13538
63. Ye, X. *et al.* (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. *Nature* 525, 256–260
64. Carreira, S. *et al.* (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. *Genes Dev.* 20, 3426–3439
65. Hoek, K.S. *et al.* (2008) *In vivo* switching of human melanoma cells between proliferative and invasive states. *Cancer Res.* 68, 650–656
66. Tirosh, I. *et al.* (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* 352, 189–196
67. Svensson, S. *et al.* (2003) Invade or proliferate? Two contrasting events in malignant behavior governed by p16<sup>INK4a</sup> and an intact Rb pathway illustrated by a model system of basal cell carcinoma. *Cancer Res.* 63, 1737–1742
68. Meijvang, J. *et al.* (2007) Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. *Mol. Biol. Cell* 18, 4615–4624

69. Huang, B. *et al.* (2013) The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. *Cell Death Dis.* 4, e682
70. Turner, D.A. *et al.* (2014) Brachyury cooperates with Wnt/ $\beta$ -catenin signalling to elicit primitive-streak-like behaviour in differentiating mouse embryonic stem cells. *BMC Biol.* 12, 63
71. Baniwal, S.K. *et al.* (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. *Mol. Cancer* 9, 258
72. Iwasaki, T. *et al.* (1995) Cell-cycle-dependent invasion *in vitro* by rat ascites hepatoma cells. *Int. J. Cancer* 63, 282–287
73. Wang, W. *et al.* (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. *Cancer Res.* 67, 3505–3511
74. Wang, W. *et al.* (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. *Cancer Res.* 64, 8585–8594
75. Goswami, S. (2004) Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy. *Cancer Res.* 64, 7664–7667
76. Qian, X. *et al.* (2013) p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis. *Oncogene* 32, 2292–2303 2303.e1–e7
77. Lehn, S. *et al.* (2010) Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. *Am. J. Pathol.* 177, 2886–2897
78. Berglund, P. *et al.* (2005) Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. *Cancer Res.* 65, 9727–9734
79. Gil-Henn, H. *et al.* (2013) Arg/Abi2 promotes invasion and attenuates proliferation of breast cancer *in vivo*. *Oncogene* 32, 2622–2630
80. Patsialou, A. *et al.* (2015) Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGF $\beta$  in claudin-low breast tumor cells. *Oncogene* 34, 2721–2731
81. Rubio, C.A. (2008) Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. *Anticancer Res.* 28, 2417–2420
82. Rubio, C.A. (2007) Difference in cell proliferation between two structurally different lesions in colorectal adenomas: high-grade dysplasia and carcinoma *in situ*. *Anticancer Res.* 27, 4321–4324
83. Rubio, C.A. (2007) Further studies on the arrest of cell proliferation in tumor cells at the invading front of colonic adenocarcinoma. *J. Gastroenterol. Hepatol.* 22, 1877–1881
84. Rubio, C.A. (2006) Cell proliferation at the leading invasive front of colonic carcinomas. Preliminary observations. *Anticancer Res.* 26, 2275–2278
85. Wassermann, S. *et al.* (2009) p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. *Gastroenterology* 136, 196–205.e2
86. Jung, A. *et al.* (2001) The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. *Am. J. Pathol.* 159, 1613–1617
87. Oshimori, N. *et al.* (2015) TGF- $\beta$  promotes heterogeneity and drug resistance in squamous cell carcinoma. *Cell* 160, 963–976
88. Abbas, T. and Dutta, A. (2009) p21 in cancer: intricate networks and multiple activities. *Nat. Rev. Cancer* 9, 400–414
89. Fero, M.L. *et al.* (1996) A syndrome of multorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. *Cell* 85, 733–744
90. Romagosa, C. *et al.* (2011) p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. *Oncogene* 30, 2087–2097
91. Tumuluri, V. *et al.* (2004) The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma. *J. Oral. Pathol. Med.* 33, 204–208
92. Dissanayake, U. *et al.* (2003) Comparison of cell proliferation in the centre and advancing fronts of oral squamous cell carcinomas using Ki-67 index. *Cell Prolif.* 36, 255–264
93. Kagawa, Y. *et al.* (2013) Cell cycle-dependent Rho GTPase activity dynamically regulates cancer cell motility and invasion *in vivo*. *PLoS One* 8, e83629
94. Gaggioli, C. (2008) Collective invasion of carcinoma cells: when the fibroblasts take the lead. *Cell Adh. Migr.* 2, 45–47
95. Harney, A.S. *et al.* (2015) Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. *Cancer Discov.* 5, 932–943
96. Gaggioli, C. *et al.* (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nat. Cell Biol.* 9, 1392–1400
97. Hawinkels, L.J. *et al.* (2014) Interaction with colon cancer cells hyperactivates TGF- $\beta$  signaling in cancer-associated fibroblasts. *Oncogene* 33, 97–107
98. Qian, L.W. *et al.* (2002) Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. *Clin. Cancer Res.* 8, 1223–1227
99. Hamilton, E. and Infante, J.R. (2016) Targeting CDK4/6 in patients with cancer. *Cancer Treat. Rev.* 45, 129–138
100. O'Leary, B. *et al.* (2016) Treating cancer with selective CDK4/6 inhibitors. *Nat. Rev. Clin. Oncol.* 13, 417–430
101. Toogood, P.L. *et al.* (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. *J. Med. Chem.* 48, 2388–2406
102. Hu, H. *et al.* (2016) Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. *Oncotarget* 7, 3171–3185
103. Dai, M. *et al.* (2012) A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGF $\beta$ -mediated breast cancer cell migration and invasion. *Breast Cancer Res.* 14, R127
104. Liu, F. and Korc, M. (2012) Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. *Mol. Cancer Ther.* 11, 2138–2148
105. Powell, A.A. *et al.* (2012) Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS One* 7, e33788
106. Gao, L. *et al.* (2014) 3D live fluorescence imaging of cellular dynamics using Bessel beam plane illumination microscopy. *Nat. Protoc.* 9, 1083–1101
107. Sakaue-Sawano, A. *et al.* (2008) Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. *Cell* 132, 487–498
108. Spencer, S.L. *et al.* (2013) The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. *Cell* 155, 369–383
109. Fu, Q. *et al.* (2016) Imaging multicellular specimens with real-time optimized tiling light-sheet selective plane illumination microscopy. *Nat. Commun.* 7, 11088
110. Weigert, R. *et al.* (2013) Imaging cell biology in live animals: ready for prime time. *J. Cell Biol.* 201, 969–979
111. Entenberg, D. *et al.* (2015) *In vivo* subcellular resolution optical imaging in the lung reveals early metastatic proliferation and motility. *Intravital* 4, (in press)
112. Manning, C.S. *et al.* (2015) Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells. *Oncogene* 34, 4320–4332
113. Zomer, A. *et al.* (2015) *In vivo* imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. *Cell* 161, 1046–1057